Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid.

EMBO molecular medicine - 1 Oct 2012

Hartkoorn Ruben C, Sala Claudia, Neres João, Pojer Florence, Magnet Sophie, Mukherjee Raju, Uplekar Swapna, Boy-Röttger Stefanie, Altmann Karl-Heinz, Cole Stewart T

Abstract excerpt

Tuberculosis, a global threat to public health, is becoming untreatable due to widespread drug resistance to frontline drugs such as the InhA-inhibitor isoniazid. Historically, by inhibiting highly vulnerable targets, natural products have been an important source of antibiotics including potent anti-tuberculosis agents. Here, we describe pyridomycin, a compound produced by Dactylosporangium fulvum with specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Biological Products

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biosynthetic Pathways

Share to Enzyme Inhibitors

Share to Mycobacterium tuberculosis

Share to Mycolic Acids

Share to Oligopeptides

Share to Oxidoreductases

Source

Open in PubMed Open full text

Identifiers

PMID: 22987724
DOI: 10.1002/emmm.201201689
PMCID: PMC3491834

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid.PMID 22987724Read ↗

Proteome-wide Profiling of Isoniazid Targets in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.Semantic proximity Read ↗

Unlocking InhA: Novel approaches to inhibit Mycobacterium tuberculosis.Semantic proximity Read ↗

Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

New and Old Hot Drug Targets in TuberculosisSemantic proximity Read ↗

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosisSemantic proximity Read ↗

Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrBSemantic proximity Read ↗

Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practiceSemantic proximity Read ↗

Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor SynthesisSemantic proximity Read ↗

In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant Mycobacterium tuberculosis.Semantic proximity Read ↗

Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.Semantic proximity Read ↗

Tuberculosis. Beating the bacillus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.